MYC and lymphoma: Daily administration of Everolimus (5 mg/kg, 6 days per week) significantly improves Eμ-MYC-bearing mice survival (upon adoptive transfer of Eμ-MYC cells) and the median OS widely varies from one Eμ-MYC lymphoma to another (125).